FAEE Stock Overview
Researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials worldwide. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Faes Farma, S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €3.20 |
52 Week High | €3.80 |
52 Week Low | €3.07 |
Beta | 0.52 |
1 Month Change | 0% |
3 Month Change | 3.57% |
1 Year Change | -15.92% |
3 Year Change | -8.84% |
5 Year Change | -12.29% |
Change since IPO | 62.17% |
Recent News & Updates
Recent updates
Shareholder Returns
FAEE | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | 0% | 4.1% | 4.1% |
1Y | -15.9% | 0.8% | 10.9% |
Return vs Industry: FAEE underperformed the UK Pharmaceuticals industry which returned -7.1% over the past year.
Return vs Market: FAEE underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
FAEE volatility | |
---|---|
FAEE Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 6.6% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.2% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: FAEE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine FAEE's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1933 | 1,764 | n/a | faesfarma.com |
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and markets pharmaceutical products and raw materials in Spain and internationally. The company's products include prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn’s disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu.
Faes Farma, S.A. Fundamentals Summary
FAEE fundamental statistics | |
---|---|
Market cap | €1.00b |
Earnings (TTM) | €89.64m |
Revenue (TTM) | €468.68m |
10.9x
P/E Ratio2.1x
P/S RatioIs FAEE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FAEE income statement (TTM) | |
---|---|
Revenue | €468.68m |
Cost of Revenue | €160.06m |
Gross Profit | €308.62m |
Other Expenses | €218.98m |
Earnings | €89.64m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.29 |
Gross Margin | 65.85% |
Net Profit Margin | 19.13% |
Debt/Equity Ratio | 1.3% |
How did FAEE perform over the long term?
See historical performance and comparisonDividends
5.0%
Current Dividend Yield40%
Payout RatioCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2023/10/03 19:00 |
End of Day Share Price | 2023/07/06 00:00 |
Earnings | 2023/06/30 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Faes Farma, S.A. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Álvaro Arístegui Echevarría | Ahorro Corporación |
Kamla Singh | AlphaValue |
Guilherme Sampaio | Banco BPI, S.A. |